Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

Basit Öğe Kaydı
dc.authoridGoktasAydin, Sabin/0000-0002-0077-6971
dc.authoridFırat, Sedat Tarık/0000-0002-2358-8260
dc.authoridSimsek, Melih/0000-0003-0633-8558
dc.authoridBilici, Ahmet/0000-0002-3192-456X
dc.authoridYasin, Ayse Irem/0000-0002-1528-8065
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridçakır, emre/0000-0003-0411-8818
dc.authorwosidCoban, Ezgi/HMP-2643-2023
dc.authorwosidGoktasAydin, Sabin/JAC-0864-2023
dc.authorwosidFırat, Sedat Tarık/HKO-6070-2023
dc.authorwosidSimsek, Melih/AFM-5523-2022
dc.authorwosidBilici, Ahmet/E-2062-2018
dc.authorwosidYasin, Ayse Irem/HNR-8404-2023
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.contributor.authorYasin, Ayse Irem
dc.contributor.authorAydin, Sabin Goktas
dc.contributor.authorSumbul, Bilge
dc.contributor.authorKoral, Lokman
dc.contributor.authorSimsek, Melih
dc.contributor.authorGeredeli, Caglayan
dc.contributor.authorOzturk, Akin
dc.date.accessioned2024-08-04T20:58:37Z
dc.date.available2024-08-04T20:58:37Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov) Plain language summary Cancer patients are at high risk for infection with SARS-CoV-2 and of developing the associated disease, COVID-19, which therefore puts them in the priority group for vaccination. This study evaluated the efficacy and safety of CoronaVac, an inactivated virus vaccine, in cancer patients. The immune response rate, defined as seropositivity, was 85.2% in the cancer patient group and 97.5% in the control group. The levels of antibodies, which are blood markers of immune response to the vaccine, were also significantly lower in the patient group, especially in those older than 60 years and receiving chemotherapy. These results highlight the importance of determining the effective vaccine type and dose in cancer patients to protect them from COVID-19 without disrupting their cancer treatment.en_US
dc.description.sponsorshipOncological Clinical Research Association (ONKAD)en_US
dc.description.sponsorshipThis study was funded by the Oncological Clinical Research Association (ONKAD). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.en_US
dc.identifier.doi10.2217/fon-2021-1248
dc.identifier.endpage1244en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue10en_US
dc.identifier.pmid35081732en_US
dc.identifier.startpage1235en_US
dc.identifier.urihttps://doi.org/10.2217/fon-2021-1248
dc.identifier.urihttps://hdl.handle.net/11616/103021
dc.identifier.volume18en_US
dc.identifier.wosWOS:000747186600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofFuture Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcanceren_US
dc.subjectchemotherapyen_US
dc.subjectCoronaVacen_US
dc.subjectCOVID-19en_US
dc.subjectCOVID-19 vaccinesen_US
dc.subjectimmunotherapyen_US
dc.subjectmalignancyen_US
dc.subjectSARS-CoV-2en_US
dc.titleEfficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu